Literature DB >> 28871704

[Analysis of clinical use of post-marketing hospital centralized monitoring of Xiyanping injection].

Ying Zhao1, Chen Shi1, Pu Huang1.   

Abstract

To assess the clinical use and occurrence of adverse reactions of Xiyanping injection, and to provide reference for rational drug use in the clinic. Based on hospital central monitoring method, the clinical data of Xiyanping injection in our hospital in 2014 was tracked and analyzed. A total of 848 inpatients were enrolled in this study. Among them, 39.9% were not in accordance with the medication purpose. In practice, the dose more than the limits prescribed by the instructions of child and adult were accounted for 1.72% and 6.62%, respectively; improper choice of solvent, accounting for 3.18%; both the choice of versus intravenous drip and aerosol inhalati administration route were reasonable; mixed with other drug, accounting for 2.24%. The incidence of ADR of Xiyanping injection was 0.12%, which showed good safety. Irrational use of Xiyanping injection existed in clinics, and the use should be strengthened and regulated. The manufacturer should improve the drug instruction of usage and dosage. Copyright© by the Chinese Pharmaceutical Association.

Entities:  

Keywords:  Xiyanping injection ; adverse reaction ; clinical use ; hospital centralized monitoring ; post-marketing reassessment

Mesh:

Substances:

Year:  2016        PMID: 28871704     DOI: 10.4268/cjcmm20160434

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  1 in total

1.  Post-marketing safety surveillance and re-evaluation of Xueshuantong injection.

Authors:  Chunxiao Li; Tao Xu; Peng Zhou; Junhua Zhang; Ge Guan; Hui Zhang; Xiao Ling; Weixia Li; Fei Meng; Guanping Liu; Linyan Lv; Jun Yuan; Xuelin Li; Mingjun Zhu
Journal:  BMC Complement Altern Med       Date:  2018-10-16       Impact factor: 3.659

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.